NCT02974504

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

A Multicenter, Randomized, Double-blind, Active-contrelled, Parallel-group, Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin After Oral Administration in Patiend With Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 207 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes

Detailed description

1. Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-24 weeks. 2. Liniagliptin 5mg Group: Administration with linagliptin 5mg for 0-12 weeks, and with Evogliptin 5mg for 13-24 weeks

Conditions

• Type2 Diabetes

Interventions

Type	Name	Description
DRUG	evogliptin	evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
DRUG	Linagliptin	linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg

Timeline

• Start date: 2016-09-01
• Primary completion: 2018-03-01
• Completion: 2018-03-01
• First posted: 2016-11-28
• Last updated: 2018-07-23

Locations

1 site across 1 country: South Korea